A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs PF-06821497 (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Oct 2019 Planned End Date changed from 25 Sep 2023 to 24 Dec 2023.
- 24 Oct 2019 Planned primary completion date changed from 25 Sep 2023 to 24 Dec 2023.
- 11 Aug 2019 Planned End Date changed from 15 Sep 2023 to 25 Sep 2023.